Arbutin

Pharmacology & Research

Arbutin is a hydroquinone glucoside — a pro-drug that is largely inert until β-glucosidase (in gut, tissue, skin or bacteria) hydrolyses it to free hydroquinone, the species that carries both its activity and its safety concern. It has two distinct faces. In cosmetics it is a tyrosinase-inhibiting skin-lightening agent — the synthetic α-arbutin anomer is more potent than the natural plant β-arbutin ^{3,4Reference 3Boissy RE et al. · 1996Arbutin: mechanism of its depigmenting action in human melanocyte cultureView study →Reference 4Sugimoto K et al. · 2004Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cellsView study →} — with small human melasma trials behind it ^{5,6Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}. In herbal medicine it is the near-exclusive active of bearberry (uva-ursi) as a urinary antiseptic, where the arbutin delivered to urine is cleaved to hydroquinone at the site of infection ^{1Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →}. The load-bearing point throughout: the hydroquinone exposure, not arbutin itself, is the pharmacologically and toxicologically decisive quantity.

1. Skin lightening

Arbutin competitively inhibits tyrosinase (it is structurally homologous to the substrate L-tyrosine), reducing melanin synthesis in cultured human melanocytes without lowering tyrosinase mRNA ^{3Reference 3Boissy RE et al. · 1996Arbutin: mechanism of its depigmenting action in human melanocyte cultureView study →}, and α-arbutin is the more potent anomer ^{4Reference 4Sugimoto K et al. · 2004Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cellsView study →}. Human evidence: an open-label melasma RCT found 3% arbutin gel reduced pigmentation ^{5Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →}, and a split-face RCT found α-arbutin 5% plus kojic acid as effective as a triple-combination (hydroquinone/tretinoin/steroid) cream with fewer adverse events ^{6Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}.

Gap: the trials are small, short and always test arbutin combined with kojic/ellagic acid and a sunscreen — no adequately powered isolate-monotherapy trial — and the herbal β-arbutin has thinner human data than α-arbutin ^{5,6Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}.

2. Urinary antiseptic (bearberry)

Arbutin is delivered largely intact to the urine, where tissue and bacterial β-glucosidase liberate hydroquinone as the proposed antibacterial agent — a conversion that needs alkaline urine to run efficiently ^{1Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →}. Human pharmacokinetics confirm the delivery: over 60% of an oral bearberry dose is recovered in urine as hydroquinone conjugates ^{1,2Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →}.

Gap: this is a property of the herb plus hydrolysis, not isolated arbutin (which is inactive until cleaved), and no modern controlled trial establishes that bearberry/arbutin cures urinary infections — the antibacterial mechanism rests on in-vitro and PK inference ^{1,10Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}.

3. Antioxidant

Arbutin is a radical scavenger in vitro, a property bundled into its antimelanogenic action ^{7Reference 7Boo YC · 2021Arbutin as a skin-depigmenting agent with antimelanogenic and antioxidant propertiesView study →}.

Gap: in-vitro only, and a weaker scavenger than the flavonols and tannins it co-occurs with in bearberry, so isolate attribution is hard ^{7Reference 7Boo YC · 2021Arbutin as a skin-depigmenting agent with antimelanogenic and antioxidant propertiesView study →}.

4. Anti-inflammatory

Arbutin suppressed LPS-induced NF-κB, COX-2 and iNOS signalling in microglial cells ^{8Reference 8Lee HJ · 2012Anti-inflammatory effects of arbutin in LPS-stimulated BV2 microglial cellsView study →}, consistent with its rodent nephroprotective data.

Gap: purely preclinical (cell and rodent), with no human anti-inflammatory endpoint ^{8Reference 8Lee HJ · 2012Anti-inflammatory effects of arbutin in LPS-stimulated BV2 microglial cellsView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Tyrosinase (competitive inhibition)	↓ melanin synthesis; α-arbutin > β-arbutin	skin lightening
β-glucosidase hydrolysis → free hydroquinone	liberates the active/toxic aglycone in gut, urine, skin, bacteria	urinary antisepsis + entire safety profile
NF-κB / COX-2 / iNOS	suppressed in stimulated cells	anti-inflammatory, nephroprotection
ROS / radical scavenging	antioxidant, complements antimelanogenesis	antioxidant, depigmentation
p21 (CDKN1A) up-regulation	anti-proliferative in bladder cancer cells	preclinical only

Pharmacokinetics

Arbutin is a phenolic glycoside hydrolysed by β-glucosidase — in the gut microbiota, intestinal/hepatic tissue and skin — to free hydroquinone, which is then conjugated to glucuronide and sulfate. After oral bearberry, over 60% of the arbutin dose is recovered in urine as hydroquinone conjugates, with free hydroquinone appearing within hours, and the conversion is pH-sensitive (favoured in alkaline, blunted in acidic urine) ^{1,2Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →}. Topically, skin β-glucosidase can likewise release small amounts of hydroquinone from applied arbutin — the mechanism behind both efficacy and the regulatory trace-hydroquinone concern. The systemic and urinary hydroquinone exposure, not arbutin, is the load-bearing quantity.

Clinical trials

Human data are two small, combination-formula cosmetic-dermatology studies — an open-label melasma RCT of 3% arbutin ^{5Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →} and a split-face RCT of α-arbutin-plus-kojic-acid ^{6Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →}. There is no robust isolated-arbutin monotherapy RCT and no modern controlled urinary-infection trial; the bearberry human record is pharmacokinetic (confirming urinary hydroquinone delivery), not efficacy ^{1,2Reference 1Schindler G et al. · 2002Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uva-ursiView study →Reference 2Quintus J et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry-leaf extractView study →}.

Last checked: July 2026.

Toxicity & Safety

The whole safety picture is governed by hydroquinone, arbutin’s hydrolysis product — which is why this page is flagged moderate rather than low. Hydroquinone is a regulated skin-lightening agent, banned from over-the-counter cosmetics in the EU and restricted/withdrawn from OTC use by the US FDA, with documented concerns over exogenous ochronosis (paradoxical bluish-black pigmentation with chronic use), skin irritation, and genotoxicity/rodent-carcinogenicity signals at high exposure; arbutin-derived hydroquinone is cytotoxic and pro-oxidant to human bladder cells at high dose in vitro ^{11Reference 11Huđek Turković A et al. · 2022Proteome changes in human bladder T24 cells induced by hydroquinone derived from ArctostaphylosView study →}. In regulatory context, the EU SCCS judged α-arbutin safe in cosmetics up to ~2% (face) provided free hydroquinone is kept to unavoidable trace levels ^{9Reference 9SCCS · 2016Opinion on the safety of the use of α-arbutin in cosmetic productsView study →}, and a risk assessment of bearberry products estimated free-hydroquinone urinary exposure at ~11 µg/kg/day at therapeutic dose, used to argue that short-course bearberry is tolerable ^{10Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}. So capped topical cosmetic use is regarded as safe, but the hydroquinone dependency — dose, formulation purity, chronic use (ochronosis/genotoxicity), and added systemic exposure with oral use — means arbutin cannot be treated as inert. (Its own preclinical literature is otherwise organ-protective — nephroprotective in acute kidney injury ^{12Reference 12Zhang B et al. · 2021Arbutin attenuates LPS-induced acute kidney injuryView study →}, anti-proliferative in bladder cancer cells ^{13Reference 13Li H et al. · 2011Arbutin inhibits TCCSUP human bladder cancer cell proliferation via up-regulation of p21View study →}, and gastroprotective in rat ulcer models ^{14Reference 14Taha MME et al. · 2012Gastroprotective activities of Turnera diffusa: role of arbutinView study →}.)

Pregnancy & lactation

Avoid. Bearberry/arbutin is contraindicated in pregnancy and lactation (and in children under 12 and renal impairment), because chronic hydroquinone exposure is undesirable and safety data in these groups are absent; short-course topical cosmetic use has not been established as safe in pregnancy either.

Dosage

There is no established safe long-term or isolated oral dose, and nothing here is a recommendation. Topically, trials used β-arbutin ~3% gel and α-arbutin 2–5% (within EU cosmetic caps of ~2% face for α-arbutin), usually combined with kojic/ellagic acid and a sunscreen over 8–12 weeks ^{5,6,9Reference 5Ertam I et al. · 2008RCTEfficiency of ellagic acid and arbutin in melasma: a randomised, prospective, open-label studyView study →Reference 6Tantanasrigul P et al. · 2025RCTTopical α-arbutin 5% and kojic acid 2% versus triple-combination cream for melasma: a split-face RCTView study →Reference 9SCCS · 2016Opinion on the safety of the use of α-arbutin in cosmetic productsView study →}. Orally, as bearberry (not the isolate), pharmacopoeial dosing is standardised to arbutin content and limited to no more than about five consecutive days and a few courses a year, with urine alkalinised to aid conversion and use contraindicated in pregnancy, lactation, children and renal disease ^{10Reference 10de Arriba SG et al. · 2013Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparationsView study →}.

References